ChemoTech contracts to US market
Vetriqure AB, the animal care division of ChemoTech, has entered into a contract with FloridaWild Veterinary Hospital, marking its entry into the US commercial marketplace. The Scandinavian-based company joined into the agreement with the Florida veterinary facility to create a “center of excellence” for data and clinical practice on various species seen at the hospital.
"We are very pleased to partner with Vetiqure to contribute to the body of evidence and work toward our shared goal of developing innovative therapies to help pets live their best lives." sais Dr. Pamela Schrager, medical director at FloridaWild Veterinary Hospital.
Through the contract between the two entities, FloridaWild will purchase treatment kits and will gain access to ChemoTech’s vetIQure TSE device on a trial basis, after which they may order. Purchase of the device will mark the first commercial installation. The companies’ collaboration was borne out of discussion at a trade show this year.
"The traction we have in the US at the moment and the interest we've received from other countries is very promising,” said Mohan Frick, chief executive officer at Vetiqure. “Growth potentials like this will allow us to improve and expand our production capacity and our logistics to match the increased demand. We will now allocate resources to our Animal Care business in the US, Europe and the Middle East to ensure that we take full advantage of the commercial and clinical opportunities in front of us.
Comments
Related Articles
Copyright © 2025 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment